Brought to you by 
Vifor Fresenius gets ex-US and Japanese rights to Relypsa's hyperkalemia therapy
24 Jul 2017
Executive Summary
Relypsa Inc. licensed Galenica Group's Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive worldwide rights (excluding the US and Japan) to commercialize the hyperkalemia therapy patiromer for oral suspension globally except in the US and Japan.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vifor Fresenius gets ex-US and Japanese rights to Relypsa's hyperkalemia therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice